We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A brighter future for melanoma.
- Authors
Russell‐Jones, R.
- Abstract
Dear Editor, Congratulations to the BJD on publishing two outstanding editorials on the medical and surgical management of melanoma.[[1]] Trials demonstrating the efficacy of adjuvant therapy in stage III disease are coming to maturity at the same time as early-completion lymphadenectomy is being shown to be ineffective in terms of overall survival, and unacceptable in terms of morbidity. As the editorial contends,[1] it is likely that disease-free survival will be followed by an improvement in overall survival, particularly as nivolumab is already known to be more effective than ipilimumab in the adjuvant setting.[4] However, adjuvant trials using interferon demonstrated only a marginal effect in terms of overall survival despite a significant effect on disease-free survival.[5] The efficacy of programmed death 1 inhibitors on disease-free survival is greater than that of interferon. What is certain is that sentinel lymph node biopsy without a completion lymphadenectomy should now become an indispensable part of any trial involving clinical patients with stage II melanoma.
- Subjects
LYMPHADENECTOMY; MELANOMA; SENTINEL lymph node biopsy
- Publication
British Journal of Dermatology, 2019, Vol 181, Issue 4, p874
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.18122